You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | n/a |
Div Cover | n/a | n/a |
Op Mrgn | -359.3% | n/a |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -1.9 | n/a |
PEG | 0.0 | n/a |
Price / Revenue | 12.9 | n/a |
Price / Book value | 1.1 |
Latest | Forecast | |
---|---|---|
Revenue | 20.1% | n/a |
PBT | 0.0% | n/a |
EPS | 0.0% | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2020-12-31 | 0.96 | -1.05 | -12.71p | 0.0 | 0.0 | n/a | n/a | 0.0% |
2021-12-31 | 1.15 | -4.14 | -8.05p | -4.0 | 0.0 | n/a | n/a | 0.0% |
GENinCode prepares for US revenue as California licence granted Sharecast News | 03 Jan |
---|---|
GENinCode inks collaboration with largest US medical school Sharecast News | 23 Mar |
GENinCode enters cholesterol collaboration with Cumbria health network Sharecast News | 15 Mar |
Second Price Monitoring Extn | 03-Jan-23 23:58 |
---|---|
Price Monitoring Extension | 03-Jan-23 23:58 |
Approval of California state license | 03-Jan-23 14:36 |
Issue of Share Options | 22-Nov-22 23:20 |
British Medical Journal publication | 03-Nov-22 14:37 |